Роль каскада циклооксигеназы-2 в метастазировании рака молочной железы
Аннотация
Современные подходы в терапии, основанные на изучении генетического портрета опухоли, все сильнее индивидуализируют ле- чебную тактику, что создает реальные перспективы выздоровления все большего числа пациенток. Экспериментальные и кли- нические данные показали, что повышенная экспрессия гена СОХ-2 увеличивает риск метастазирования рака молочной железы (РМЖ) в отдаленные органы. В ряде исследований последних лет обнаружено, что селективные ингибиторы фермента СОХ-2 способны тормозить пролиферацию, индуцировать апоптоз клеток РМЖ и угнетать неоангиогенез в опухоли. Однако в этой области много неясных и спорных вопросов, экспериментальное решение которых еще впереди. Наш обзор посвящен теоретическим предпосылкам и анализу результатов исследований роли COX-2 в метастазировании РМЖ.
Ключевые слова
рак молочной железы,
СOX-2,
СOX-1,
простагландины,
PGE2,
сигнальный путь,
маркеры метастазирования,
мишени для таргетной терапии
Об авторах
М. А. Таипов
ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
И. А. Кудрявцев
ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
К. П. Лактионов
ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
Н. Е. Левченко
ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
В. Е. Шевченко
ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва
Россия
Россия
Список литературы
1. Matsuda T., Saika K. Worldwide burden of cancer incidence in 2002 extrapolated from cancer incidence in five continents Vol. IX. Jpn J Clin Oncol 2012;42(11):1111–2.
2. Bray F., McCarron P., Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004;6(6):229–39.
3. Yako-Suketomo H., Saika K .Worldwide burden of cancer incidence below the age of 40 in 2002 extrapolated from the Cancer Incidence in Five Continents Vol. IX. Jpn J Clin Oncol 2013;43(3):343–4.
4. Статистика злокачественных новообразований в России и странах СНГ в 2009 году. Под ред. М.И. Давыдова, Е.М. Аксель. Вестн РОНЦ 2011;22(3 Прил 1):3–170.
5. Comen E., Norton L., Massague J. Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. J Clin Oncol 2011;29(19):2610–2.
6. Wiwanitkit V. Combination of EGFR and COX-2 inhibitors in breast cancer patient. Tumour Biol 2012;33(4):1261.
7. Petersen M., Pardali E., van der Horst G. et al. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene 2010;29(9):1351–61.
8. Basolo F., Fiore L., Ciardiello F. et al. Response of normal and oncogene- transformed human mammary epithelial cells to transforming growth factor beta 1 (TGF- beta 1): lack of growth-inhibitory effect on cells expressing the simian virus 40 large-T antigen. Int J Cancer 1994;56(5):736–42.
9. Ashok V., Dash C., Rohan T.E. et al. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 2011;20(1):66–70.
10. Fu J.Y., Masferrer J.L., Seibert K. et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265(28):16737–40.
11. Xie W.L., Chipman J.G., Robertson D.L. et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88(7):2692–6.
12. Kraemer S.A., Meade E.A., DeWitt D.L. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5'-flanking regulatory sequences. Arch Biochem Biophys 1992;293(2):391–400.
13. Garavito R.M., DeWitt D.L. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta 1999;1441(2–3):278–87.
14. Jana D., Sarkar D.K., Maji A. et al. Can cyclo-oxygenase-2 be a useful prognostic and risk stratification marker in breast cancer? J Indian Med Assoc 2012;110(7):429–33.
15. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97–120.
16. DeWitt D.L., Meade E.A., Smith W.L. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993;95(2A):40S–44S.
17. Taiwo Y.O., Levine J.D. Indomethacin blocks central nociceptive effects of PGF2 alpha. Brain Res 1986;373(1–2):81–4.
18. Boie Y., Stocco R., Sawyer N. et al. Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 1997;340(2–3):227–41.
19. Marcus A.J. Transcellular metabolism of eicosanoids. Prog Hemost Thromb 1986;8:127–42.
20. Марусов И.В., Марусова И.Б., Игнатов Ю.Д. и др. Современные направления фармакологической коррекции эффектов липидных медиаторов воспаления: Научный обзор. Ученые записки СП(б)ГМУ им. акад. И.П. Павлова 2001;8(2):7–57.
21. Brandão R.D., Veeck J., Van de Vijver K.K. et al. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti- tumour transcriptional response in primary breast cancer. Breast Cancer Res 2013;15(2):R29.
22. Ma X., Holt D., Kundu N. et al. A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2013;2(1):e22647.
23. Bakhle Y.S. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001;134(6):1137–50.
24. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94(4):252–66.
25. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001;1(1):11–21.
26. Wang D., Mann J.R., DuBois R.N. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 2005;128(5):1445–61.
27. Masferrer J.L., Koki A., Seibert K. COX-2 inhibitors. A new class of angiogenic agents. Ann NY Acad Sci 1999;889:84–6.
28. Wang D., DuBios R.N. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci USA 2004;101(2):415–6.
29. Khasar S.G., Gold M.S., Levine J.D. A tetrodotoxin - resistant sodium current mediates inflammatory pain in the rat. Neurosci Lett 1998;256(1):17–20.
30. Collins D.R., Davies S.N. Arachidonic acid metabolites and the synaptic potentiation evoked by activation of metabotropic glutamate receptors. Eur J Pharmacol 1998;342(2–3):213–6.
31. Cuzick J., Dowsett M., Pineda S. et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29(32):4273–8.
32. Cho M.H., Yoon J.H., Jaegal Y.J. et al. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma. Breast 2006;15(3):390–8.
33. de Roos M.A., de Bock G.H., de Vries J. et al. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 2007;140(1):109–14.
34. Yiu G.K., Toker A. NFAT induces breast cancer cell invasion by promoting the induction of cyclooxygenase-2. J Biol Chem 2006;281(18):12210–7.
35. Howe L.R. Inflammation, breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9(4):210.
36. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17(5):1474–81.
37. Kerlikowske K., Molinaro A.M., Gauthier M.L. et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102(9):627–37.
38. Subbaramaiah K., Morris P.G., Zhou X.K. et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2(4):356–65.
39. Wang D., DuBois R.N. The role of the PGE2-aromatase pathway in obesity- associated breast inflammation. Cancer Discov 2012;2(4):308–10.
40. Sandra N., Ester P., Marie-Agnès P. et al. The DHEA metabolite 7β-hydroxy- epiandrosterone exerts anti-estrogenic effects on breast cancer cell lines. Steroids 2012;77(5):542–51.
41. Wang J., Xiao X., Zhang Y. et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res 2012;53(1):77–90.
42. Bronger H., Kraeft S., Schwarz-Boeger U. et al. Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer. Breast Cancer Res 2012;14(1):R30.
43. Holt D.M., Ma X., Kundu N. et al. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 2012;35(2):179–88.
44. Reader J., Holt D., Fulton A. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011;30(3–4):449–63.
45. Gao X., Nawaz Z. Progesterone receptors – animal models and cell signaling in breast cancer role of steroid receptor coactivators and corepressors of progesterone receptors in breast cancer. Breast Cancer Res 2002;4(5):182–6.
46. Thill M., Hoellen F., Becker S. et al. Expression of prostaglandin- and vitamin D- metabolising enzymes in benign and malignant breast cells. Anticancer Res 2012;32(1):367–72.
47. Xin X., Majumder M., Girish G.V. et al. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Invest 2012;92(8):1115–28.
48. Murata T., Aritake K., Matsumoto S. et al. Prostaglandin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci USA 2011;108(49):19802–7.
49. Murata T., Lin M.I., Aritake K. et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci USA 2008;105(50):20009–14.
50. Monroe D.G., McGee-Lawrence M.E., Oursler M.J., Westendorf J.J. Update on Wnt signaling in bone cell biology and bone disease. Gene. 2012;492(1):1–18.
51. Ara T., Declerk Y.A. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010;46(7):1223–31.
52. Soto-Guzman A., Villegas-Comonfort S., Cortes-Reynosa P., Perez Salazar E. Role of arachidonic acid metabolism in Stat5 activation induced by oleic acid in MDA- MB-231 breast cancer cells. Prostaglandins Leukot Essent Fatty Acids 2013;88(3):243–9.
Для цитирования:
Таипов М.А., Кудрявцев И.А., Лактионов К.П., Левченко Н.Е., Шевченко В.Е. Роль каскада циклооксигеназы-2 в метастазировании рака молочной железы. Опухоли женской репродуктивной системы. 2013;(3-4):12-17. https://doi.org/10.17650/1994-4098-2013-0-3-4-12-17
For citation:
Taipov M.A., Kudryavtsev I.A., Laktionov K.P., Levchenko N.E., Shevchenko V.E. Role of a cyclooxygenase-2 cascade in breast cancer cell dissemination. Tumors of female reproductive system. 2013;(3-4):12-17. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-3-4-12-17
Просмотров: 199
Послать статью по эл. почте 